The cardiovascular safety of antiobesity drugs—analysis of signals in the FDA Adverse Event Report System Database

I am glad and proud to announce that a paper which I helped to prepare and publish is available on the Nature’s group site.

The paper, The cardiovascular safety of antiobesity drugs—analysis of signals in the FDA Adverse Event Report System Database, by Einat Gorelik et al. (including myself) analyzes the data in the FDA Adverse Event Reporting System (FAERS). In this study, we found interesting and relevant safety information about the long-term safety of the antiobesity drug Lorcaserin. Due to the interdisciplinary nature of the paper, the review process took about a year. Interestingly enough, the FDA requested the withdrawal of Lorcaserin due to long-term safety issues but not the ones we studied.